BRPI0905917A2 - Vírus mutante da família flaviviridae, composição farmacêutica, ácido nucléico, proteína de capsídeo de vírus mutado, método para produzir um vírus modificado e método para produzir um ácido nucléico modificado - Google Patents

Vírus mutante da família flaviviridae, composição farmacêutica, ácido nucléico, proteína de capsídeo de vírus mutado, método para produzir um vírus modificado e método para produzir um ácido nucléico modificado

Info

Publication number
BRPI0905917A2
BRPI0905917A2 BRPI0905917-2A BRPI0905917A BRPI0905917A2 BR PI0905917 A2 BRPI0905917 A2 BR PI0905917A2 BR PI0905917 A BRPI0905917 A BR PI0905917A BR PI0905917 A2 BRPI0905917 A2 BR PI0905917A2
Authority
BR
Brazil
Prior art keywords
virus
producing
nucleic acid
modified
pharmaceutical composition
Prior art date
Application number
BRPI0905917-2A
Other languages
English (en)
Inventor
Franz X Heinz
Christian Mandl
Petra Schlick
Andreas Meinke
Original Assignee
Intercell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag filed Critical Intercell Ag
Publication of BRPI0905917A2 publication Critical patent/BRPI0905917A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0905917-2A 2008-02-08 2009-02-06 Vírus mutante da família flaviviridae, composição farmacêutica, ácido nucléico, proteína de capsídeo de vírus mutado, método para produzir um vírus modificado e método para produzir um ácido nucléico modificado BRPI0905917A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08101404 2008-02-08
PCT/EP2009/051351 WO2009098277A1 (en) 2008-02-08 2009-02-06 Flaviviridae mutants comprising a deletion in the capsid protein for use as vaccines

Publications (1)

Publication Number Publication Date
BRPI0905917A2 true BRPI0905917A2 (pt) 2015-08-04

Family

ID=40673966

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0905917-2A BRPI0905917A2 (pt) 2008-02-08 2009-02-06 Vírus mutante da família flaviviridae, composição farmacêutica, ácido nucléico, proteína de capsídeo de vírus mutado, método para produzir um vírus modificado e método para produzir um ácido nucléico modificado

Country Status (8)

Country Link
US (1) US8715999B2 (pt)
EP (1) EP2240509A1 (pt)
JP (1) JP2011510672A (pt)
CN (1) CN101970467A (pt)
AU (1) AU2009211379B2 (pt)
BR (1) BRPI0905917A2 (pt)
CA (1) CA2713400A1 (pt)
WO (1) WO2009098277A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410634B (de) * 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
SMT201900445T1 (it) 2011-06-08 2019-09-09 Translate Bio Inc Composizione di nanoparticelle lipidiche e metodi per il rilascio di mrna
CN113215117B (zh) * 2021-05-17 2022-09-06 四川农业大学 一种鸭坦布苏病毒致弱活疫苗候选株及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05506230A (ja) 1990-04-06 1993-09-16 ジーンラブス　テクノロジイズ　インコーポレイテッド Ｃ型肝炎ウイルスエピトープ
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
CA2425152A1 (en) * 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
CA2495294C (en) 2002-08-13 2012-06-12 Akzo Nobel Nv Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines

Also Published As

Publication number Publication date
JP2011510672A (ja) 2011-04-07
WO2009098277A1 (en) 2009-08-13
US20100323003A1 (en) 2010-12-23
CA2713400A1 (en) 2009-08-13
AU2009211379B2 (en) 2014-08-21
AU2009211379A1 (en) 2009-08-13
EP2240509A1 (en) 2010-10-20
US8715999B2 (en) 2014-05-06
CN101970467A (zh) 2011-02-09

Similar Documents

Publication Publication Date Title
BRPI0814939A2 (pt) Entidade química, composição farmacêutica, e, método para tratar uma infecção viral em um mamífero.
BRPI0916689A2 (pt) composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida.
BRPI0921651A2 (pt) Método para produzir adenovírus recombinante, e partículas virais, e, biorreator
BR112014002621A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento
IL210485A (en) An isolated antibody or its functional protein, a process for making it, a pharmaceutical preparation containing it, and an isolated amino acid encoding an antibody or a functional protein
BRPI1006141A2 (pt) composições de anticorpo modificado, métodos para preparar e usar as mesmas
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
BRPI0914918A2 (pt) forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida.
HUE046579T2 (hu) Folyamat és eszköz anyagok vagy tüzelõanyagok elõállítására
BRPI0908092A2 (pt) Edulcorante, método para preparar uma composição edulcorante, e, composição edulcorante
BRPI1008145A2 (pt) proteína de ligação de antígeno biespecífico, método para preparação de uma proteína de ligação de antígeno biespecífico, célula hospedeira, composição farmacêutica, uso da proteína de ligação de antígeno biespecífico e método para o tratamento de um paciente.
BRPI1007161A2 (pt) composição farmacêutica oral, e processo para preparar uma composição
BRPI0921507A2 (pt) composição, método de preparação de um excipiente, comprimido farmacêutico e método de preparação do mesmo
BRPI0915142A2 (pt) polipeptídeos, ácido nucleico e usos dos mesmos
BRPI0818680A2 (pt) composição farmacêutica, preparação farmacêutica, e método para preparar um forma de dosagem oral farmacêutica
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
BRPI0912403A2 (pt) pasta aquosa, concreto, e, métodos para preparar uma pasta aquosa e para preparar um concreto
IL217016A0 (en) Method for replicating influenza virus in culture
BRPI0719272A2 (pt) Composição de enzima, e, método para preparar uma composição de enzima.
BRPI0811499A2 (pt) Métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
DK2512453T4 (da) Granulater til farmaceutiske præparater, fremgangsmåder og apparat til deres fremstilling
BRPI1007211A2 (pt) composição farmacêutica oral em uma forma sólida, e, processo para preparar uma composição.
BRPI0822472A2 (pt) Método, camundongo, e, composição
BRPI0820644A2 (pt) método de preparação de uma composição, e, composição

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]